524717 — Titan Biotech Income Statement
0.000.00%
- IN₹3.52bn
- IN₹3.49bn
- IN₹1.56bn
- 89
- 30
- 21
- 43
Annual income statement for Titan Biotech, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | R2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,422 | 1,235 | 1,440 | 1,641 | 1,565 |
Cost of Revenue | |||||
Gross Profit | 777 | 550 | 606 | 729 | 838 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 986 | 946 | 1,171 | 1,331 | 1,352 |
Operating Profit | 436 | 289 | 269 | 310 | 213 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 427 | 290 | 281 | 315 | 244 |
Provision for Income Taxes | |||||
Net Income After Taxes | 317 | 217 | 210 | 237 | 183 |
Minority Interest | |||||
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 303 | 217 | 248 | 249 | 215 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 303 | 217 | 248 | 249 | 215 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 37 | 26.2 | 30.1 | 30.1 | 26.1 |
Dividends per Share |